SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    United Network for Organ Sharing. http://www.unos.org. Accessed July 2012.
  • 2
    European Liver Transplant Registry. http://www.eltr.org. Accessed July 2012.
  • 3
    Gelson W, Hoare M, Dawwas MF, Vowler S, Gibbs P, Alexander G. The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation 2011; 91: 1240-1244.
  • 4
    Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011; 11: 1226-1235.
  • 5
    Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91.
  • 6
    Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427.
  • 7
    Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97: 72-81.
  • 8
    Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155-167.
  • 9
    Aberg F, Pukkala E, Höckerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl 2008; 14: 1428-1436.
  • 10
    Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891-1901.
  • 11
    Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant 2010; 10: 1889-1896.
  • 12
    Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6( pt 1): 1017-1024.
  • 13
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62: 370-375.
  • 14
    Collins MH, Montone KT, Leahey AM, Hodinka RL, Salhany KE, Belchis DA, Tomaszewski JE. Autopsy pathology of pediatric posttransplant lymphoproliferative disorder. Pediatrics 2001; 107: E89.
  • 15
    Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009; 27: 3354-3362.
  • 16
    Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353.
  • 17
    Marqués E, Jiménez C, Manrique A, Vallejo GH, Clemares M, Ortega P, Moreno E. Development of lymphoproliferative disease after liver transplantation. Transplant Proc 2008; 40: 2988-2989.
  • 18
    Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90: 1521-1527.
  • 19
    Opelz G, Daniel V, Naujokat C, Döhler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962-967.
  • 20
    Saha A, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res 2011; 17: 3056-3063.
  • 21
    Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24: 375-385.
  • 22
    Dotti G, Fiocchi R, Motta T, Gamba A, Gotti E, Gridelli B, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000; 69: 827-833.
  • 23
    Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103: 748-755.
  • 24
    Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173-192.
  • 25
    Allen U, Alfieri C, Preiksaitis J, Humar A, Moore D, Tapiero B, et al.; for Canadian PTLD Workshop Group– 1999. Epstein-Barr virus infection in transplant recipients: summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis 2002; 13: 89-99.
  • 26
    Hoshida Y, Li T, Dong Z, Tomita Y, Yamauchi A, Hanai J, Aozasa K. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001; 91: 869-875.
  • 27
    Fernández MC, Bes D, De Dávila M, López S, Cambaceres C, Dip M, Imventarza O. Post-transplant lymphoproliferative disorder after pediatric liver transplantation: characteristics and outcome. Pediatr Transplant 2009; 13: 307-310.
  • 28
    Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, et al.; for Haemato-Oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010; 149: 675-692.
  • 29
    Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772-778.
  • 30
    Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038-1046.
  • 31
    Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007; 25: 4902-4908.
  • 32
    Richendollar BG, Tsao RE, Elson P, Jin T, Steinle R, Pohlman B, Hsi ED. Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leuk Lymphoma 2009; 50: 2005-2012.
  • 33
    Zimmermann H, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, et al. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German posttransplant lymphoproliferative disorder registry. Transplantation 2012; 93: 543-550.
  • 34
    Trofe J, Buell JF, Beebe TM, Hanaway MJ, First MR, Alloway RR, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5( pt 1): 775-780.
  • 35
    Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055-4063.
  • 36
    Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981.
  • 37
    Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002; 236: 429-436.
  • 38
    Molmenti EP, Nagata DE, Roden JS, Squires RH, Molmenti H, Fasola CG, et al. Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population. Am J Transplant 2001; 1: 356-359.
  • 39
    Montserrat E. PTLD treatment: a step forward, a long way to go. Lancet Oncol 2012; 13: 120-121.
  • 40
    Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (★). Am J Transplant 2011; 11: 336-347.
  • 41
    Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088.
  • 42
    Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587.
  • 43
    Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Pediatr Gastroenterol Nutr 2001; 33: 445-449.
  • 44
    Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-1525.
  • 45
    Ozçay F, Arslan H, Bilezikçi B, Sevmiş S, Moray G, Haberal M. The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients. Transplant Proc 2009; 41: 2878-2880.
  • 46
    Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001; 3: 97-103.
  • 47
    Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59: 240-244.
  • 48
    Izadi M, Fazel M, Saadat SH, Taheri S. Radiotherapy is the best treatment method in post transplant lymphoproliferative disorders localizing in brain: a review of the literature. Ann Transplant 2011; 16: 126-133.
  • 49
    Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005; 104: 1661-1667.
  • 50
    Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057.
  • 51
    Trappe RU, Choquet S, Reinke P, Dreyling M, Mergenthaler HG, Jäger U, et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: the role of single-agent rituximab. Transplantation 2007; 84: 1708-1712.
  • 52
    Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456-473.
  • 53
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al.; for German PTLD Study Group and European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
  • 54
    Buell JF, Gross TG, Hanaway MJ, Trofe J, Muthiak C, First MR, et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37: 956-957.
  • 55
    Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273-274.
  • 56
    Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009; 137: 2010-2017.
  • 57
    Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 1172-1181.
  • 58
    Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161( suppl 3): 78-84.
  • 59
    Herrero JI, Pardo F, D'Avola D, Alegre F, Rotellar F, Iñarrairaegui M, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl 2011; 17: 402-408.
  • 60
    Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002; 8: 939-944.
  • 61
    Herrero JI, España A, Quiroga J, Sangro B, Pardo F, Alvárez-Cienfuegos J, Prieto J. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl 2005; 11: 1100-1106.
  • 62
    Christenson LJ, Cherikh WS, Otley CC, Salasche SJ, Kauffman HM. Allograft and overall survival of patients with posttransplant skin cancer. Dermatol Surg 2011; 37: 183-191.
  • 63
    Tessari G, Naldi L, Boschiero L, Nacchia F, Fior F, Forni A, et al. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol 2010; 146: 294-299.
  • 64
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691.
  • 65
    Baccarani U, Adani GL, Serraino D, Lorenzin D, Gambato M, Buda A, et al. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. Transplant Proc 2009; 41: 1303-1305.
  • 66
    Hinten F, Meeuwis KA, van Rossum MM, de Hullu JA. HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients. Crit Rev Oncol Hematol; doi:10.1016/j.critrevonc.2012.02.008.
  • 67
    Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst 2011; 103: 1827-1839.
  • 68
    Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007; 7: 599-612.
  • 69
    Albright JB, Bonatti H, Stauffer J, Dickson RC, Nguyen J, Harnois D, et al. Colorectal and anal neoplasms following liver transplantation. Colorectal Dis 2010; 12: 657-666.
  • 70
    Hanouneh IA, Macaron C, Lopez R, Zein NN, Lashner BA. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2012; 18: 269-274.
  • 71
    Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993; 36: 908-912.
  • 72
    Loftus EV Jr, Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998; 27: 685-690.
  • 73
    Gantt S, Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011; 24: 295-301.
  • 74
    Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Mühlbacher F, Salat A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl Int 2004; 17: 366-369.
  • 75
    Veroux M, Corona D, Scalia G, Garozzo V, Gagliano M, Giuffrida G, et al. Surveillance of human papilloma virus infection and cervical cancer in kidney transplant recipients: preliminary data. Transplant Proc 2009; 41: 1191-1194.
  • 76
    Li MR, Chen GH, Cai CJ, Wang GY, Zhao H. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence. Digestion 2011; 84: 134-141.
  • 77
    Morita K, Taketomi A, Soejima Y, Ikegami T, Fukuhara T, Iguchi T, et al. De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. Liver Transpl 2009; 15: 1412-1416.
  • 78
    Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-1227.
  • 79
    Nishihori T, Strazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer 2008; 7: 260-266.
  • 80
    Parikshak M, Pawlak SE, Eggenberger JC, Lee CS, Szilagy EJ, Margolin DA. The role of endoscopic colon surveillance in the transplant population. Dis Colon Rectum 2002; 45: 1655-1660.
  • 81
    Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003; 75: 1983-1988.
  • 82
    Eaden JA, Mayberry JF; for British Society for Gastroenterology and Association of Coloproctology for Great Britain and Ireland. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002; 51( suppl 5): V10-V12.
  • 83
    Génébès C, Brouchet L, Kamar N, Lepage B, Prévot G, Rostaing L, et al. Characteristics of thoracic malignancies that occur after solid-organ transplantation. J Thorac Oncol 2010; 5: 1789-1795.
  • 84
    Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh G, Reyes J, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193-1200.
  • 85
    Duvoux C, Delacroix I, Richardet JP, Roudot-Thoraval F, Métreau JM, Fagniez PL, et al. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 1999; 67: 418-421.
  • 86
    Paternoster DM, Cester M, Resente C, Pascoli I, Nanhorngue K, Marchini F, et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 2008; 40: 1877-1880.
  • 87
    Terhorst D, Drecoll U, Stockfleth E, Ulrich C. Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure. Br J Dermatol 2009; 161( suppl 3): 85-89.
  • 88
    Herrero JI. Screening of de novo tumors after liver transplantation. J Gastroenterol Hepatol 2012; 27: 1011-1016.
  • 89
    Finkenstedt A, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009; 9: 2355-2361.
  • 90
    Otley CC, Maragh SL. Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy. Dermatol Surg 2005; 31: 163-168.
  • 91
    Duman S, Töz H, Aşçi G, Alper S, Ozkahya M, Unal I, et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 2002; 17: 892-896.
  • 92
    Uemura T, Riley TR, Khan A, Hollenbeak C, Schreibman I, Ghahramani N, et al. Immune functional assay for immunosuppressive management in post-transplant malignancy. Clin Transplant 2011; 25: E32E37.
  • 93
    de Gruijl FR, Koehl GE, Voskamp P, Strik A, Rebel HG, Gaumann A, et al. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer 2010; 127: 796-804.
  • 94
    Datta D, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, Pal S. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res 2009; 69: 8902-8909.
  • 95
    Suthanthiran M, Hojo M, Maluccio M, Boffa DJ, Luan FL. Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy. Trans Am Clin Climatol Assoc 2009; 120: 369-388.
  • 96
    O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-1874.
  • 97
    Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-2960.
  • 98
    O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 1186-1191.
  • 99
    Braconnier P, Del Marmol V, Broeders N, Kianda M, Massart A, Lemy A, et al. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study. Nephrol Dial Transplant 2012; 27: 2547-2553.
  • 100
    Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
  • 101
    Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619-2625.
  • 102
    Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628.
  • 103
    Tjon AS, Sint Nicolaas J, Kwekkeboom J, de Man RA, Kazemier G, Tilanus HW, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010; 16: 837-846.
  • 104
    Melosky B, Karim M, Chui A, McBride M, Cameron EC, Yeung CK, et al. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J Am Soc Nephrol 1992; 2( suppl): S290-S294.
  • 105
    Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004; 91: 1420-1424.
  • 106
    Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120: 747-759.
  • 107
    Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
  • 108
    Khokhar NZ, Altman JK, Platanias LC. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 2011; 23: 578-586.
  • 109
    Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-449.
  • 110
    Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, et al.; for Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92: 303-310.
  • 111
    Flechner SM, Glyda M, Cockfield S, Grinyó J, Legendre Ch, Russ G, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633-1644.
  • 112
    Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146-1156.
  • 113
    Schnitzbauer AA, Schlitt HJ, Geissler EK. Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence. Transplantation 2011; 91: 1173-1176.
  • 114
    Ariza-Heredia EJ, Razonable RR. Human herpes virus 8 in solid organ transplantation. Transplantation 2011; 92: 837-844.